About Contact Us Careers
Sign In

Rheumatic Myocarditis Treatment Market Size & Share, by Age Group (Under 5 years, 5-15 years, 15-40 years, Above 40 years); Diagnosis (Blood Tests, Echocardiogram, Electrocardiogram); Treatment (Anticonvulsant Medications, Surgery); End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3325
  • Published Date: Mar 21, 2023
  • Report Format: PDF, PPT

Companies Dominating the Rheumatic Myocarditis Treatment Landscape

top-features-companies
    • Siemens Healthcare GmbH
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • CryoLife Inc.
    • Edwards Lifesciences Corporation
    • Neovasc Inc.
    • HighLife SAS
    • Abbott Laboratories
    • Sanofi-aventis Groupe
    • Pfizer Inc.
    • Boston Scientific Corporation
    • Medtronic PLC 
Browse Key Market Insights with Data Illustration:

In the News

  • Siemens Healthcare GmbH has launched the technologically-advanced multidisciplinary angiography system ARTIS icono. With its development, the company is expected to cater to different needs of cardiovascular interventions, interventional radiology, neuroradiology, and vascular interventions.

  • Pfizer Inc. has finally acquired Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company that is dedicated to the discovery, development, and delivery of life-changing treatments for patients diagnosed with sickle cell disease (SCD). The acquisition is anticipated to broaden the offerings provided by the company.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3325
  • Published Date: Mar 21, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising prevalence of rheumatic fever and the growing availability of over-the-counter drugs are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2035.

Risks and complications associated with surgery coupled with high costs associated with the treatment and less awareness level about the disease are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Siemens Healthcare GmbH, CryoLife Inc., Edwards Lifesciences Corporation, Neovasc Inc., HighLife SAS, Abbott Laboratories, Sanofi-aventis Groupe, Pfizer Inc., Boston Scientific Corporation, Medtronic PLC, and other key players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by age group, diagnosis, treatment, end-user, and by region.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying